Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 22

1.

Statistical modelling of HER2-positivity in breast cancer: Final analyses from two large, multicentre, non-interventional studies in Germany.

Rüschoff J, Lebeau A, Sinn P, Schildhaus HU, Decker T, Ammann J, Künzel C, Koch W, Untch M.

Breast. 2020 Feb;49:246-253. doi: 10.1016/j.breast.2019.12.005. Epub 2019 Dec 18.

2.

Human epidermal growth factor receptor 2-positive digestive tumors.

Wagner AD, Özdemir BC, Rüschoff J.

Curr Opin Oncol. 2019 Jul;31(4):354-361. doi: 10.1097/CCO.0000000000000544.

PMID:
31170116
3.

HER2 testing in gastric cancer diagnosis: insights on variables influencing HER2-positivity from a large, multicenter, observational study in Germany.

Baretton G, Kreipe HH, Schirmacher P, Gaiser T, Hofheinz R, Berghäuser KH, Koch W, Künzel C, Morris S, Rüschoff J; Nicht-interventionelle Untersuchung (NIU) HER2 Study Group.

Virchows Arch. 2019 May;474(5):551-560. doi: 10.1007/s00428-019-02541-9. Epub 2019 Mar 2.

PMID:
30826877
4.

FGFR3 mRNA overexpression defines a subset of oligometastatic colorectal cancers with worse prognosis.

Fromme JE, Schmitz K, Wachter A, Grzelinski M, Zielinski D, Koppel C, Conradi LC, Homayounfar K, Hugo T, Hugo S, Lukat L, Rüschoff J, Ströbel P, Ghadimi M, Beißbarth T, Reuter-Jessen K, Bleckmann A, Schildhaus HU.

Oncotarget. 2018 Aug 14;9(63):32204-32218. doi: 10.18632/oncotarget.25941. eCollection 2018 Aug 14.

5.

Optimization and validation of PD-L1 immunohistochemistry staining protocols using the antibody clone 28-8 on different staining platforms.

Koppel C, Schwellenbach H, Zielinski D, Eckstein S, Martin-Ortega M, D'Arrigo C, Schildhaus HU, Rüschoff J, Jasani B.

Mod Pathol. 2018 Nov;31(11):1630-1644. doi: 10.1038/s41379-018-0071-1. Epub 2018 Jun 26.

6.

Physical basis of the 'magnification rule' for standardized Immunohistochemical scoring of HER2 in breast and gastric cancer.

Scheel AH, Penault-Llorca F, Hanna W, Baretton G, Middel P, Burchhardt J, Hofmann M, Jasani B, Rüschoff J.

Diagn Pathol. 2018 Mar 12;13(1):19. doi: 10.1186/s13000-018-0696-x.

7.

Interlaboratory concordance of PD-L1 immunohistochemistry for non-small-cell lung cancer.

Scheel AH, Baenfer G, Baretton G, Dietel M, Diezko R, Henkel T, Heukamp LC, Jasani B, Jöhrens K, Kirchner T, Lasitschka F, Petersen I, Reu S, Schildhaus HU, Schirmacher P, Schwamborn K, Sommer U, Stoss O, Tiemann M, Warth A, Weichert W, Wolf J, Büttner R, Rüschoff J.

Histopathology. 2018 Feb;72(3):449-459. doi: 10.1111/his.13375. Epub 2017 Nov 21.

PMID:
28851100
8.

HER2 testing in gastric cancer: results of a German expert meeting.

Lordick F, Al-Batran SE, Dietel M, Gaiser T, Hofheinz RD, Kirchner T, Kreipe HH, Lorenzen S, Möhler M, Quaas A, Röcken C, Rüschoff J, Tannapfel A, Thuss-Patience P, Baretton G.

J Cancer Res Clin Oncol. 2017 May;143(5):835-841. doi: 10.1007/s00432-017-2374-x. Epub 2017 Mar 11. Review.

9.

Assessing HER2 testing quality in breast cancer: variables that influence HER2 positivity rate from a large, multicenter, observational study in Germany.

Rüschoff J, Lebeau A, Kreipe H, Sinn P, Gerharz CD, Koch W, Morris S, Ammann J, Untch M; Nicht-interventionelle Untersuchung (NIU) HER2 Study Group.

Mod Pathol. 2017 Feb;30(2):217-226. doi: 10.1038/modpathol.2016.164. Epub 2016 Oct 21.

10.

[HER2 testing in gastric cancer - results of a German expert meeting].

Lordick F, Al-Batran SE, Hofheinz RD, Lorenzen S, Thuss-Patience P, Baretton GB, Dietel M, Gaiser T, Kirchner T, Kreipe HH, Quaas A, Röcken C, Rüschoff J, Tannapfel A.

Z Gastroenterol. 2016 Aug;54(8):791-6. doi: 10.1055/s-0042-110794. Epub 2016 Aug 16. Review. German.

PMID:
27529529
11.

[HER2 testing in gastric cancer : Results of a meeting of German experts].

Baretton G, Dietel M, Gaiser T, Kirchner T, Kreipe HH, Quaas A, Röcken C, Rüschoff J, Tannapfel A, Lordick F, Al-Batran S, Hofheinz R, Lorenzen S, Moehler M, Thuss-Patience P.

Pathologe. 2016 Jul;37(4):361-6. doi: 10.1007/s00292-016-0179-3. German.

PMID:
27376648
12.

Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab: A Secondary Analysis of the HERA Trial.

Loi S, Dafni U, Karlis D, Polydoropoulou V, Young BM, Willis S, Long B, de Azambuja E, Sotiriou C, Viale G, Rüschoff J, Piccart MJ, Dowsett M, Michiels S, Leyland-Jones B.

JAMA Oncol. 2016 Aug 1;2(8):1040-7. doi: 10.1001/jamaoncol.2016.0339.

PMID:
27100299
13.

Image-based computational quantification and visualization of genetic alterations and tumour heterogeneity.

Zhong Q, Rüschoff JH, Guo T, Gabrani M, Schüffler PJ, Rechsteiner M, Liu Y, Fuchs TJ, Rupp NJ, Fankhauser C, Buhmann JM, Perner S, Poyet C, Blattner M, Soldini D, Moch H, Rubin MA, Noske A, Rüschoff J, Haffner MC, Jochum W, Wild PJ.

Sci Rep. 2016 Apr 7;6:24146. doi: 10.1038/srep24146.

14.

Impact of updated HER2 testing guidelines in breast cancer--re-evaluation of HERA trial fluorescence in situ hybridization data.

Stoss OC, Scheel A, Nagelmeier I, Schildhaus HU, Henkel T, Viale G, Jasani B, Untch M, Rüschoff J.

Mod Pathol. 2015 Dec;28(12):1528-34. doi: 10.1038/modpathol.2015.112. Epub 2015 Sep 25.

15.

HER-2 and HER-3 expression in liver metastases of patients with colorectal cancer.

Styczen H, Nagelmeier I, Beissbarth T, Nietert M, Homayounfar K, Sprenger T, Boczek U, Stanek K, Kitz J, Wolff HA, Ghadimi BM, Middel P, Liersch T, Rüschoff J, Conradi LC.

Oncotarget. 2015 Jun 20;6(17):15065-76.

16.

MET gene copy number alterations and expression of MET and hepatocyte growth factor are potential biomarkers in angiosarcomas and undifferentiated pleomorphic sarcomas.

Schmitz K, Koeppen H, Binot E, Fassunke J, Künstlinger H, Ihle MA, Heydt C, Wardelmann E, Büttner R, Merkelbach-Bruse S, Rüschoff J, Schildhaus HU.

PLoS One. 2015 Apr 6;10(4):e0120079. doi: 10.1371/journal.pone.0120079. eCollection 2015.

17.

Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.

Lorenzen S, Riera Knorrenschild J, Haag GM, Pohl M, Thuss-Patience P, Bassermann F, Helbig U, Weißinger F, Schnoy E, Becker K, Stocker G, Rüschoff J, Eisenmenger A, Karapanagiotou-Schenkel I, Lordick F.

Eur J Cancer. 2015 Mar;51(5):569-76. doi: 10.1016/j.ejca.2015.01.059. Epub 2015 Feb 16.

PMID:
25694417
18.

MET amplification status in therapy-naïve adeno- and squamous cell carcinomas of the lung.

Schildhaus HU, Schultheis AM, Rüschoff J, Binot E, Merkelbach-Bruse S, Fassunke J, Schulte W, Ko YD, Schlesinger A, Bos M, Gardizi M, Engel-Riedel W, Brockmann M, Serke M, Gerigk U, Hekmat K, Frank KF, Reiser M, Schulz H, Krüger S, Stoelben E, Zander T, Wolf J, Buettner R.

Clin Cancer Res. 2015 Feb 15;21(4):907-15. doi: 10.1158/1078-0432.CCR-14-0450. Epub 2014 Dec 9.

19.

HER2 testing in gastric cancer: a practical approach.

Rüschoff J, Hanna W, Bilous M, Hofmann M, Osamura RY, Penault-Llorca F, van de Vijver M, Viale G.

Mod Pathol. 2012 May;25(5):637-50. doi: 10.1038/modpathol.2011.198. Epub 2012 Jan 6.

20.

HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing.

Rüschoff J, Dietel M, Baretton G, Arbogast S, Walch A, Monges G, Chenard MP, Penault-Llorca F, Nagelmeier I, Schlake W, Höfler H, Kreipe HH.

Virchows Arch. 2010 Sep;457(3):299-307. doi: 10.1007/s00428-010-0952-2. Epub 2010 Jul 28.

Supplemental Content

Loading ...
Support Center